Get Live Data

Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada
Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in CanadaView Video
Roundtable Discussion; The Future of Mineral Sands
Roundtable Discussion; The Future of Mineral SandsView Video

Latest Share Chat

  2. Share Prices
  3. Hikma Pharmaceuticals Share Price
  4. Hikma Pharmaceuticals Share Regulatory News
  5. Hikma Pharmaceuticals

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Hikma Pharmaceuticals Information

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,925.00
Bid: 1,925.00
Ask: 1,927.00
Change: -10.00 (-0.52%)
Spread: 2.00 (0.104%)
Open: 1,938.00
High: 1,942.00
Low: 1,924.00
Prev. Close: 1,935.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Hikma Pharmaceuticals

23 Jun 2020 17:30

RNS Number : 8326Q
FTSE Russell
23 June 2020
 

 

 

 

 

Hikma Pharmaceuticals (UK): Shares in Issue and Investability Weight ChangeChanges in FTSE UK Index Series

23 June 2020

Following the receipt of updated shareholder information for Hikma Pharmaceuticals, (UK, constituent) as a result of a secondary placing and concurrent share repurchase, please see details of affected indexes and effective dates below:

 

 

Index

Effective FromStart of Trading

FTSE 100 Index

26 June 2020

FTSE 350 Index

26 June 2020

FTSE All-Share Index

26 June 2020

FTSE 350 Lower Yield Index

26 June 2020

 

* The change to Index shares reflects the secondary placing only.

 

 

 

 

 

 

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia

+1800 653 680

Hong Kong

+852 2164 3333

Japan

+81 3 4563 6346

London

+44 (0) 20 7866 1810

New York

+1866 551 0617

 

Alternatively please visit our website at www.ftserussell.com

Terms of Use | Copyright © 2020 FTSE Russell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FTSSEMFDDESSEIM
456789101112
Date   Source Headline
30th May 20183:20 pmRNSDirector/PDMR Shareholding
30th May 20189:00 amRNSHikma launches Methylergonovine Maleate Tablets
23rd May 201810:20 amRNSDirector/PDMR Shareholding
18th May 20181:01 pmRNSAGM Results
18th May 20187:00 amRNSTrading Statement
17th May 20181:45 pmRNSDirector/PDMR Shareholding
17th May 20181:10 pmRNSDirector/PDMR Shareholding
15th May 20182:26 pmRNSDirector/PDMR Shareholding
3rd May 20189:00 amRNSHikma launches Methotrexate Injection
1st May 20181:38 pmRNSTotal Voting Rights
26th Apr 20181:40 pmRNSHolding(s) in Company
25th Apr 201810:41 amRNSBlock listing Interim Review
24th Apr 20189:00 amRNSHikma expands licensing agreement with Rovi
20th Apr 20189:00 amRNSHikma launches Dexrazoxane for Injection
19th Apr 201812:00 pmRNSAnnual Financial Report and Notice of AGM
10th Apr 20182:34 pmRNSDirector/PDMR Shareholding
3rd Apr 201811:19 amRNSTotal Voting Rights
29th Mar 20189:00 amRNSHikma launch-Palonosetron Hydrochloride Injection
20th Mar 20189:00 amRNSHikma has launched Ritonavir Tablets USP
19th Mar 20183:50 pmRNSDirector/PDMR Shareholding
14th Mar 20187:00 amRNSFinal Results
12th Mar 20187:00 amRNSUpdate status on ANDA for generic Advair Diskus®
9th Mar 20189:21 amRNSBlock Listing Application
27th Feb 201812:23 pmRNSNotice of Results
20th Feb 20187:00 amRNSSigurdur Olafsson appointed CEO of Hikma
13th Feb 20184:43 pmRNSHolding(s) in Company
8th Feb 201812:41 pmRNSDirector/PDMR Shareholding
8th Feb 201812:39 pmRNSDirector/PDMR Shareholding
8th Feb 201812:37 pmRNSDirector/PDMR Shareholding
26th Jan 20184:56 pmRNSHolding(s) in Company
17th Jan 20185:22 pmRNSHolding(s) in Company
15th Jan 20188:00 amRNSHikma Appoints Dr. Surendera Tyagi
4th Jan 201811:19 amRNSTotal Voting Rights
19th Dec 20179:00 amRNSHikma reaches licensing agreement with Celltrion
13th Dec 20179:00 amRNSHikma- Dihydroergotamine Mesylate Injection, USP
12th Dec 20179:59 amRNSHolding(s) in Company
11th Dec 20179:33 amRNSHolding(s) in Company
1st Dec 20179:28 amRNSTotal Voting Rights
30th Nov 20175:47 pmRNSHikma Ventures- $20.5m Series C round for Prognos
28th Nov 201710:24 amRNSAnnouncement
27th Nov 20171:38 pmRNSHikma Ventures invests in Biolinq
22nd Nov 20179:32 amRNSHolding(s) in Company
20th Nov 20179:32 amRNSHolding(s) in Company
14th Nov 20178:47 amRNSHolding(s) in Company
14th Nov 20177:00 amRNSHikma Acquires Products from Boehringer Ingelheim
8th Nov 20174:45 pmRNSHolding(s) in Company
2nd Nov 20172:51 pmRNSHolding(s) in Company
1st Nov 201711:43 amRNSTotal Voting Rights
30th Oct 20179:26 amRNSHikma launches Pantoprazole Sodium for Injection
5th Oct 20179:49 amRNSBlock listing Interim Review
456789101112

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.